Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hangzhou's AnHeart Completes $14.6 Million A Funding from Decheng

publication date: May 17, 2019

AnHeart Therapeutics of Hangzhou raised $14.6 million in a Series A round from Decheng Capital, a China life science investor. AnHeart uses its expertise in global clinical development to develop innovative products, which it partners at near-term value inflection points. In late 2018, AnHeart in-licensed global rights to an oral, highly selective ROS1/NTRK small molecule inhibitor from Daiichi Sankyo. AB-106 is in two Phase I clinical trials in the US and Japan. After the Phase I trial, AnHeart will assume responsibility for further clinical development. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here